Table 3.
Targeting the Signaling Pathways of BCSCs in Clinical Trials.
| Targeted Signaling Pathway | Agent | Study Phase | Clinicaltrials.gov Identifier | Study Status | Type/Stage of Breast Cancer |
|---|---|---|---|---|---|
| Wnt Signaling Pathway | Vantictumab | I | NCT01973309 | Completed | Metastatic HER2-Negative Breast Cancer |
| Foxy-5 | I | NCT02020291 | Completed | Metastatic Breast Cancer | |
| Cirmtuzumab with Paclitaxel I | I | NCT02776917 | Active, not Recruiting | Breast Neoplasms | |
| LGK974 | I | NCT01351103 | Recruiting | TNBC | |
| Notch Signaling Pathway | MK-0752 (GSI) | I | NCT00106145 | Completed | Advanced Breast Cancer |
| MK-0752 (GSI) with Docetaxel | I/II | NCT00645333 | Completed | Metastatic Breast Cancer | |
| PF-03084014 | II | NCT02299635 | Terminated | Advanced-Stage TNBC | |
| PF-03084014 with Docetaxel 260 | I | NCT01876251 | Terminated | Advanced-Stage TNBC | |
| Melatonin with Vitamin D | II | NCT01965522 | Completed | Early-Stage Breast Cancer | |
| Hedgehog Signaling pathway | Vismodegib with Neoadjuvant Paclitaxel, Cyclophosphamide, and Epirubicin | II | NCT02694224 | Recruiting | TNBC |
| Taladegib | I | NCT02784795 | Completed | Metastatic Breast Cancer | |
| Itraconazole | Unknown | NCT00798135 | Completed | Metastatic/Non-Metastatic Breast Cancer | |
| Itraconazole with Capivasertib | I | NCT04712396 | Completed | Metastatic TNBC/HR2-Positive Breast Cancer |